Spruce Biosciences, Inc. Stock Price, News & Analysis

Spruce Biosciences, Inc. (Nasdaq: SPRB) has appointed Dr. Kirk Ways to its board of directors, enhancing its leadership during a crucial growth phase. Dr. Ways, with over 30 years in pharmaceutical drug discovery, previously was Chief Medical Officer at Nuvelution Pharma and held key roles at Johnson & Johnson. His expertise in clinical development will support Spruce's program for tildacerfont, aimed at treating rare endocrine disorders, including congenital adrenal hyperplasia. The company is focused on delivering innovative therapies for patients with significant unmet medical needs.

Spruce Biosciences (Nasdaq: SPRB) has published results from two Phase 2 clinical studies of tildacerfont for treating classic congenital adrenal hyperplasia (CAH). The studies demonstrated tildacerfont's ability to significantly reduce key hormone levels, including ACTH and androstenedione, particularly in patients with poor disease control. In 60% of cases, normalization of ACTH was observed. The findings support ongoing late-stage trials (CAHmelia-203 and CAHmelia-204) aimed at further assessing tildacerfont's efficacy and its potential to reduce glucocorticoid dosage.

Spruce Biosciences, Inc. (Nasdaq: SPRB) presented promising data from its Phase 2 clinical trial of tildacerfont for treating classic congenital adrenal hyperplasia (CAH) at the 23rd European Congress of Endocrinology. The open-label study showed significant reductions in disease-driving hormones such as ACTH, 17-OHP, and A4 in patients with poor disease control, achieving up to 84% reduction in ACTH levels. Notably, 60% of patients experienced normalization of ACTH levels without increasing steroid doses. The ongoing CAHmelia program aims to further evaluate the treatment's potential to reduce glucocorticoid usage.

Spruce Biosciences (Nasdaq: SPRB), a biopharmaceutical company, announced that CEO Richard King will participate in a virtual fireside chat at the RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 PM EDT. Interested parties can access the live webcast through the company's investor relations website and an archived replay will be available for 30 days post-event. Spruce is focused on developing therapies for rare endocrine disorders, including its product candidate tildacerfont, aimed at treating classic congenital adrenal hyperplasia and a specific form of polycystic ovary syndrome.

Spruce Biosciences (Nasdaq: SPRB) reported its first-quarter financial results for 2021, highlighting advancements in therapies for rare endocrine disorders. The company has $148.6 million in cash, enabling it to progress its clinical trials, including the Phase 2 program for pediatric classic congenital adrenal hyperplasia (CAH). R&D expenses rose to $6.7 million, while G&A expenses climbed to $3.1 million, resulting in a net loss of $9.9 million. The company plans to submit an IND for polycystic ovary syndrome and initiate critical trials later in the year.

Spruce Biosciences, Inc. (Nasdaq: SPRB) reported its Q4 and 2020 financial results, marking a transformative year in developing therapies for rare endocrine disorders.

Key updates include the initiation of the CAHmelia program for classic congenital adrenal hyperplasia and plans for Phase 2 trials in pediatric classic CAH and PCOS. The company has $157.2 million in cash, enhancing its ability to fund ongoing clinical studies. R&D expenses rose significantly to $23.9 million, with a net loss of $29.5 million reported for the year.

Spruce Biosciences (Nasdaq: SPRB) presented promising results from its Phase 2 trials of tildacerfont for treating congenital adrenal hyperplasia (CAH) at the Endocrine Society’s 2021 Annual Meeting. Data showed significant reductions in key biomarkers: 84% in ACTH, 80% in 17-OHP, and 79% in A4 levels after 12 weeks. The drug was well tolerated, with no new safety concerns. Tildacerfont aims to be the first non-steroidal therapy for CAH, highlighting a significant milestone for patients who have lacked novel treatments for decades.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company, announced that it will present data from its Phase 1 and 2 trials of tildacerfont for classic congenital adrenal hyperplasia (CAH) at the ENDO 2021 Annual Meeting from March 20-23. Key presentations include results from a 12-week Phase 2 trial and assessments of steroid hormones during the study. Tildacerfont aims to provide a novel non-steroidal therapy, addressing a significant unmet need in CAH, which has lacked new treatments for about 50 years.

Spruce Biosciences (Nasdaq: SPRB), a late-stage biopharmaceutical company, has announced participation in two investor conferences. CEO Richard King will engage in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 24 at 9:00am PST. Additionally, he will take part in a panel discussion on March 2 at the 41st Cowen Annual Healthcare Conference at 11:10am PST. Interested parties can access live webcasts on the company’s website, with replays available for 30 days.